Arexis

Arexis receives European patent on a novel target for diabetes treatment

6/8/2005 9:00 AM EST

The drug development company Arexis AB announced today that it has received a European patent covering the skeletal muscle specific γ3 subunit of AMPK, representing an important part of Arexis’ patent portfolio in the AMPK field. Arexis is currently developing a novel oral therapy based on a non-insulin dependent mechanism for type II diabetes, with AMPK as target.
The granted patent – ‘Variants of the gamma...

Rein Seensalu joins Arexis as Vice President Clinical Science and Development

5/30/2005 2:00 AM EST

GOTHENBURG, SWEDEN – 30 May 2005 – the drug development company Arexis AB announced today that Rein Seensalu has joined the company, taking charge of the clinical development with the position as Vice President Clinical Science and Development. Rein Seensalu most recently held the position as Medical and Science Director at Novo Nordisk A/S and brings with him extensive management and clinical experience.

Arexis enters into collaboration with CMC Biopharmaceuticals for the production ...

3/7/2005 6:00 AM EST

GOTHENBURG, SWEDEN – 7 March 2005 – The drug development company Arexis AB announced today that it has entered into a collaboration agreement with the Danish company CMC Biopharmaceuticals on the production of recombinant human BSSL for the upcoming cystic fibrosis and preterm infant clinical trials.
The collaboration represents an important step in the preparations for the BSSL (bile salt-stimulated lipase)...

Arexis’ SCCE project receives VINNOVA grant

2/21/2005 8:00 AM EST

GOTHENBURG, SWEDEN – 21 February 2005 – The Gothenburg-based drug development company Arexis AB announced today that it has received a grant totalling SEK 6.4 million from the Swedish Agency for Innovation Systems, VINNOVA
The project will evaluate the enzyme SCCE (Stratum Corneum Chymotryptic Enzyme) as target molecule for skin disorders, in order to develop new treatments for skin disease. Already, there is...

Arexis obtains orphan drug designation in the EU for novel cystic fibrosis thera...

2/8/2005 4:00 AM EST

GOTHENBURG, SWEDEN –8 February 2005 – The Gothenburg-based drug development company Arexis AB today announced that the European Commission has granted orphan drug status for BSSL, the novel human enzyme replacement therapy for treatment of fat malabsorption in patients with cystic fibrosis. ”The orphan drug designation further underlines the positive results in our clinical trials and supports Arexis’ development...

AREXIS PRESENTS SUCCESSFUL PHASE II RESULTS OF NOVEL THERAPY FOR CYSTIC FIBROSIS

10/18/2004 4:07 AM EST

Improved lipid uptake and reduced need for pancreatic enzyme supplementation in patients with cystic fibrosis

ST LOUIS, MISSOURI - 18 October 2004 - The Gothenburg-based drug development company Arexis AB presented last Friday the results of a successful Phase II clinical trial on their novel human enzyme replacement therapy for treatment of fat malabsorption in patients with cystic fibrosis.

Arexis in Commercial Collaboration with Beiersdorf around Novel Skin Care Concep...

10/11/2004 4:09 AM EST

GOTHENBURG, SWEDEN - 11 October 2004 - The Gothenburg-based drug development company Arexis AB today announced a commercial agreement with the German corporation Beiersdorf - one of the leading international branded goods manufacturers - around the development of new compounds for the skin care market. This agreement is the result of an ongoing, productive R&D collaboration between the two companies. The novel...

AREXIS GETS EU FUNDING FOR A CLINICAL STUDY ON IMPROVED NUTRITION IN PRETERM INF...

9/22/2004 6:08 AM EST

GOTHENBURG, SWEDEN - 22 September 2004 - The Gothenburg-based drug development company Arexis AB today announced that its novel project on bile salt-stimulated lipase (BSSL), an enzyme present in human milk, has received financial support from the EU. A clinical Phase II trial will commence in 2005.

The study is part of the EU´s 6th Framework initiative EARNEST, which includes integrated epidemiological,...

Arexis acquires project in lipid metabolism

2/17/2004 6:00 AM EST

Arexis has acquired a project concerning human bile salt stimulated
lipase, BSSL, from AstraZeneca. The aim of the project is to develop a
new type of substitution therapy for patients suffering from pancreatic
dysfunction, for example for those with cystic fibrosis, and also for
preterm infants.

The acquisition includes transfer of intellectual property and know how
within the...

Arexis AB has today initiated a phase II clinical study in the area of lipid met...

7/8/2003 9:31 AM EST

Arexis AB has today initiated a phase II clinical study in the area of
lipid metabolism. The study will be completed before the end of this
year. Further details will be released shortly.

Arexis AB is a drug discovery and development company, pioneering the
use of genetics in highly selected disease models to pinpoint specific
genes involved in multifactorial metabolic and...

Releases - Arexis

Found press releases